How should antithrombotic therapy be managed in an 85-year-old male with acute cerebrovascular accident, atrial fibrillation, coronary artery disease, and a gastrointestinal bleed who is currently on clopidogrel (Plavix), aspirin, and apixaban (Eliquis)?

Immediate Management: Stop All Antithrombotic Therapy Until GI Bleeding Resolves

In this 85-year-old with active GI bleeding on triple therapy (Plavix, aspirin, Eliquis), immediately discontinue all three agents until hemostasis is achieved and the bleeding source is identified and treated endoscopically 1, 2.

Acute Phase Management

Stop Everything Now

• Discontinue aspirin, clopidogrel, and apixaban immediately
• Active GI bleeding is an absolute contraindication to continuing any antithrombotic therapy
• Consider reversal agents only if bleeding is life-threatening or hemodynamically unstable and not controlled by initial resuscitation 2
• Perform urgent endoscopy to identify and treat the bleeding source

Critical Timing Consideration

The acute CVA complicates this significantly. You must balance:

• Risk of hemorrhagic transformation of the stroke (favors delaying anticoagulation)
• Risk of stroke extension or recurrent thromboembolism (favors earlier anticoagulation)

Resumption Strategy After Bleeding Control

Timeline for Restarting Anticoagulation Post-CVA

Wait 2-14 days after the acute stroke before restarting anticoagulation, depending on stroke size and hemorrhagic transformation risk 1. For this 85-year-old with GI bleeding:

• Obtain brain imaging to assess stroke size and exclude hemorrhage
• If small stroke without hemorrhage: consider restart at 3-7 days
• If moderate-large stroke: wait closer to 14 days
• If any hemorrhagic transformation: delay further or avoid

Definitive Long-Term Regimen (After Both Bleeding and Stroke Stabilize)

The optimal regimen is apixaban (DOAC) plus clopidogrel, WITHOUT aspirin 3, 1, 4.

Here's the specific algorithm:

Step 1: Determine Time Since Acute CVA

• If <12 months post-stroke: Dual therapy (apixaban + clopidogrel) 1
• If >12 months post-stroke: Anticoagulation alone (apixaban monotherapy) 1

Step 2: Assess CAD Status

For the CAD component, determine if there was recent ACS or PCI:

• If ACS/PCI <12 months ago: Continue dual therapy (apixaban + clopidogrel) for up to 12 months total 3, 1
• If ACS/PCI >12 months ago: Anticoagulation alone (apixaban monotherapy) 3, 1
• If stable CAD without recent intervention: Anticoagulation alone 3

Step 3: Given This Patient's GI Bleed History

Drop aspirin permanently 3, 4. The 2024 ESC guidelines explicitly recommend early aspirin cessation (≤1 week) in AF patients with ACS/PCI, continuing only DOAC + P2Y12 inhibitor 3. The AUGUSTUS trial demonstrated that aspirin significantly increases bleeding (HR 1.81-1.86) without reducing ischemic events in this population 4.

Specific Recommendation for This Patient

Most likely optimal regimen: Apixaban 5mg twice daily + Clopidogrel 75mg daily (NO aspirin)

Duration depends on timing:

• Continue dual therapy if <12 months from either the CVA or any CAD intervention
• Transition to apixaban monotherapy after 12 months 3, 1

Apixaban Dosing Adjustment

Use apixaban 2.5mg twice daily (reduced dose) only if patient has ≥2 of these criteria 5:

• Age ≥80 years (✓ - he's 85)
• Weight ≤60 kg (unknown)
• Creatinine ≥1.5 mg/dL (unknown)

If he meets 2+ criteria, use the lower dose.

Critical Pitfalls to Avoid

1. Do NOT continue triple therapy - The combination of DOAC + DAPT dramatically increases bleeding risk, especially post-GI bleed 3, 4

2. Do NOT use warfarin - DOACs (especially apixaban) have lower GI bleeding rates than warfarin and better outcomes in this population 6, 4

3. Do NOT restart anticoagulation too early post-stroke - Risk of hemorrhagic transformation peaks in first 2 weeks 1

4. Do NOT keep aspirin long-term - Aspirin provides minimal additional ischemic benefit when combined with anticoagulation but substantially increases bleeding 3, 4

5. Do NOT forget GI prophylaxis - Consider PPI therapy to reduce recurrent GI bleeding risk 2

If Bleeding Recurs on This Regimen

Consider these sequential de-escalation steps:

1. Switch from clopidogrel + apixaban to apixaban monotherapy (if >12 months from acute events)
2. Evaluate for left atrial appendage occlusion as alternative to anticoagulation
3. In extreme cases with recurrent life-threatening bleeding, may need to discontinue all antithrombotic therapy with shared decision-making, accepting increased stroke risk 1

The key principle: In AF patients with recent CVA, CAD, and GI bleeding, anticoagulation for stroke prevention takes priority over antiplatelet therapy for CAD, and aspirin should be eliminated first 3, 1.